STOCK TITAN

Idexx (IDXX) insider sales: 7,143 shares sold for $4.50M in Rule 144 filings

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Idexx Laboratories insider transaction disclosed via Form 144. The filing reports a proposed sale of 1,200 common shares through Morgan Stanley Smith Barney with an aggregate market value of $787,840.20. The shares were acquired by exercise on 08/06/2025 and payment was made in cash. With 80,004,694 shares outstanding, the proposed sale represents approximately 0.0015% of the company’s outstanding common stock.

The filing also lists three sales by NIMRATA K HUNT on 08/06/2025 totaling 7,143 shares and gross proceeds of $4,503,160.86. The filer affirms they are not aware of any material nonpublic adverse information about the issuer.

Positive

  • Form 144 filed in compliance with Rule 144, providing broker, acquisition, and payment details as required.
  • The proposed sale of 1,200 shares represents approximately 0.0015% of the 80,004,694 shares outstanding, which is immaterial to total capitalization.

Negative

  • None.

Insights

TL;DR: Insider exercised options and is selling a small block — 1,200 shares worth $787,840 — with related sales totaling 7,143 shares for $4.50M.

The filing documents a routine Rule 144 notice: acquisition by exercise on 08/06/2025 and a proposed brokered sale via Morgan Stanley Smith Barney. The primary metric is the size: 1,200 shares equals ~0.0015% of the 80,004,694 shares outstanding, which is immaterial to capitalization. Recent aggregated insider sales (7,143 shares, $4,503,160.86) are disclosed, but the filing gives no indication of undisclosed adverse facts. Impact on supply or market float is minimal based on stated figures.

TL;DR: Filing appears compliant with Rule 144; insider attests no undisclosed material adverse information.

The Form 144 provides required information: acquisition date, nature (exercised shares), payment method (cash), broker details, and recent insider sales. The attestation that the filer does not possess undisclosed material adverse information is standard and included. No governance red flags (e.g., sudden unexpected executive departure or regulatory disclosures) are present in the provided content. The disclosure supports procedural transparency rather than signaling material corporate change.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for Idexx (IDXX) report?

The Form 144 reports a proposed sale of 1,200 common shares through Morgan Stanley Smith Barney with an aggregate market value of $787,840.20.

Who is the seller named in the filing?

The recent sales listed in the filing were executed by NIMRATA K HUNT, with an address at One IDEXX Drive, Westbrook, ME.

When were the securities acquired and how were they paid for?

The securities to be sold were acquired by exercise on 08/06/2025 and payment was made in cash.

How many shares were sold by the insider in the past three months per the filing?

The filing discloses three sales on 08/06/2025 totaling 7,143 shares with combined gross proceeds of $4,503,160.86.

What portion of outstanding shares does the proposed 1,200-share sale represent?

Based on 80,004,694 shares outstanding reported, the 1,200-share proposed sale represents about 0.0015% of outstanding common stock.
IDEXX Laboratories

NASDAQ:IDXX

IDXX Rankings

IDXX Latest News

IDXX Latest SEC Filings

IDXX Stock Data

54.95B
79.30M
0.68%
97.52%
2.56%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States
WESTBROOK